Jaume Capdevila
About
Jaume Capdevila is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Jaume Capdevila has authored 41 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Oncology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jaume Capdevila's work include Thyroid Cancer Diagnosis and Treatment (39 papers), Cancer-related Molecular Pathways (7 papers) and Radiomics and Machine Learning in Medical Imaging (5 papers). Jaume Capdevila is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (39 papers), Cancer-related Molecular Pathways (7 papers) and Radiomics and Machine Learning in Medical Imaging (5 papers). Jaume Capdevila collaborates with scholars based in Spain, United States and France. Jaume Capdevila's co-authors include Enrique Grande, Neda Stjepanovic, Bruce Robinson, Steven I. Sherman, Marcia S. Brose, Barbara Jarząb, Martin Schlumberger, Juan J. Díez, Ana O. Hoff and Fernanda Vaisman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Clinical Endocrinology & Metabolism.
In The Last Decade
Jaume Capdevila
38 papers receiving 988 citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jaume Capdevila Spain | 18 | 758 | 277 | 158 | 150 | 150 | 41 | 1.0k | ||
| Tomohiro Enokida Japan | 15 | 242 0.3× | 333 1.2× | 191 1.2× | 130 0.9× | 58 0.4× | 60 | 703 | ||
| John Frye United States | 10 | 230 0.3× | 286 1.0× | 172 1.1× | 222 1.5× | 51 0.3× | 24 | 754 | ||
| Melina Flanagan United States | 11 | 152 0.2× | 190 0.7× | 113 0.7× | 95 0.6× | 67 0.4× | 25 | 540 | ||
| J. Trad Wadsworth United States | 17 | 161 0.2× | 283 1.0× | 152 1.0× | 316 2.1× | 79 0.5× | 41 | 975 | ||
| Amy Prawira Canada | 11 | 134 0.2× | 326 1.2× | 147 0.9× | 172 1.1× | 36 0.2× | 38 | 621 | ||
| Domenico Guarneri Italy | 14 | 138 0.2× | 223 0.8× | 276 1.7× | 62 0.4× | 68 0.5× | 52 | 607 | ||
| Woo‐Song Ha South Korea | 18 | 209 0.3× | 219 0.8× | 257 1.6× | 205 1.4× | 19 0.1× | 49 | 861 | ||
| Marcus V. Sadi Brazil | 10 | 117 0.2× | 86 0.3× | 426 2.7× | 174 1.2× | 99 0.7× | 22 | 632 | ||
| Marilyn Mulay United States | 11 | 134 0.2× | 365 1.3× | 250 1.6× | 243 1.6× | 21 0.1× | 17 | 644 | ||
| Constantijne H. Mom Netherlands | 17 | 63 0.1× | 425 1.5× | 221 1.4× | 397 2.6× | 82 0.5× | 57 | 1.1k |
Countries citing papers authored by Jaume Capdevila
Since
Specialization
Citations
This map shows the geographic impact of Jaume Capdevila's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaume Capdevila with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaume Capdevila more than expected).
Fields of papers citing papers by Jaume Capdevila
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jaume Capdevila. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaume Capdevila. The network helps show where Jaume Capdevila may publish in the future.
Co-authorship network of co-authors of Jaume Capdevila
This figure shows the co-authorship network connecting the top 25 collaborators of Jaume Capdevila. A scholar is included among the top collaborators of Jaume Capdevila based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaume Capdevila. Jaume Capdevila is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Brose, Marcia S., Bruce Robinson, Lori J. Wirth, et al.. (2024). Comparative patient-reported tolerability (PRT): A multiplicity-controlled analysis of LIBRETTO-531, a randomized controlled trial (RCT) in medullary thyroid cancer (MTC).. Journal of Clinical Oncology. 42(16_suppl). 11111–11111.
2.
Brose, Marcia S., Jaume Capdevila, Rossella Elisei, et al.. (2024). Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy. Endocrine Related Cancer. 31(8).
3.
Oh, Do‐Youn, Alain P. Algazi, Jaume Capdevila, et al.. (2023). Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study. Cancer. 129(8). 1195–1204.
4.
Capdevila, Jaume, Jolanta Krajewska, Jorge Hernando, et al.. (2023). Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 34(3). 347–359.
5.
Capdevila, Jaume, Désirèe Deandreis, Cosimo Durante, et al.. (2023). Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice. European Thyroid Journal. 12(5).
6.
Capdevila, Jaume, A L Klochikhin, Sophie Leboulleux, et al.. (2022). A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. Thyroid. 32(5). 515–524.
7.
Capdevila, Jaume, Ahmad Awada, Dagmar Führer‐Sakel, Sophie Leboulleux, & Patrick Pauwels. (2022). Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era. Cancer Treatment Reviews. 106. 102380–102380.
8.
Brose, Marcia S., Bruce Robinson, Steven I. Sherman, et al.. (2021). Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 22(8). 1126–1138.
9.
Taylor, Matthew H., Shunji Takahashi, Jaume Capdevila, et al.. (2021). Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. Thyroid. 31(8). 1226–1234.
10.
Capdevila, Jaume, Ignacio Matos, Francesco M. Mancuso, et al.. (2019). Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. Molecular Cancer Therapeutics. 19(1). 312–317.
11.
Vuong, Huy Gia, An Thi Nhat Ho, Jaume Capdevila, et al.. (2019). Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta‐analysis. Head & Neck. 41(8). 2823–2829.
12.
Capdevila, Jaume, Kate Newbold, Lisa Licitra, et al.. (2018). Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer. Cancer Treatment Reviews. 69. 164–176.
13.
Riesco‐Eizaguirre, Garcilaso, Juan C. Galofré, Enrique Grande, et al.. (2015). Spanish consensus for the management of patients with advanced radioactive iodine refractory differentiated thyroid cancer. Endocrinología y Nutrición. 63(4). e17–e24.
14.
Galofré, Juan C., Jaume Capdevila, Elena Navarro González, et al.. (2015). Consensus on the management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI). Endocrinología y Nutrición. 62(4). e37–e46.
15.
Capdevila, Jaume & Neda Stjepanovic. (2014). Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics. 8. 129–129.
16.
Grande, Enrique, Jaume Capdevila, Juan J. Díez, Federico Longo, & Alfredo Carrato. (2013). A significant response to sunitinib in a patient with anaplastic thyroid carcinoma. SHILAP Revista de lepidopterología.
17.
Grande, Enrique, Michael C. Kreißl, Sébastiano Filetti, et al.. (2013). Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies. Advances in Therapy. 30(11). 945–966.
18.
Capdevila, Jaume, L. Iglesias, Irene Halperín, et al.. (2012). Sorafenib in metastatic thyroid cancer. Endocrine Related Cancer. 19(2). 209–216.
19.
Brose, Marcia S., Johannes W. A. Smit, Jaume Capdevila, et al.. (2012). Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. Expert Review of Anticancer Therapy. 12(9). 1137–1147.
20.
Capdevila, Jaume, José Manuel Pérez-García, Gabriel Obiols, & Josep Tabernero. (2009). Targeted therapies in thyroid cancer. Targeted Oncology. 4(4). 275–285.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Tomohiro Enokida Breakdown of academic impact, for papers by John Frye Breakdown of academic impact, for papers by Melina Flanagan Breakdown of academic impact, for papers by J. Trad Wadsworth Breakdown of academic impact, for papers by Amy Prawira Breakdown of academic impact, for papers by Domenico Guarneri Breakdown of academic impact, for papers by Woo‐Song Ha Breakdown of academic impact, for papers by Marcus V. Sadi Breakdown of academic impact, for papers by Marilyn Mulay Breakdown of academic impact, for papers by Constantijne H. Mom